Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte(TM) for the Treatment of Cutaneous T-Cell Lymphoma

Stock Information for Soligenix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soligenix Inc.

Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte(TM) for the Treatment of Cutaneous T-Cell Lymphoma
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Soligenix Announces Closing of $7.5 Million Public Offering
Soligenix Announces Pricing of $7.5 Million Public Offering
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.